Sagimet Biosciences Q3 net loss widens 48% to $19.15 million
SGMT•Sagimet Biosciences’ third-quarter net loss widened 48% year over year to $19.15 million, while research and development expenses rose 68% to $16.34 million. The company had $275.82 million in cash, cash equivalents and marketable securities at September 30, 2026, and expects current operations to be funded through mid-2029.
1. Quarterly results and outlook
Sagimet Biosciences’ third-quarter net loss widened 48% year over year to $19.15 million, and research and development expenses rose 68% to $16.34 million. Cash, cash equivalents and marketable securities totaled $275.82 million at September 30, 2026. The U.S. AURORA Phase 3 acne trial began dosing in October, with topline denifanstat data expected in the second half of 2027; current operations are expected to be funded through mid-2029, including the Phase 3 data readout and potential NDA submission.
